Annexon Posts $51.2M Q3 Loss, Adds $200M Oxford Credit Facility Ahead of Q4 BLA Filing
ANNX sits 67% above its 52-week low of $2.54.
Summary
Annexon closed Q3 with a $51.2 million net loss, or $0.25 per share, narrower than the $54.9 million loss a year earlier, and $213.4 million in cash and short-term investments that management says funds operations into 2028. R&D fell to $41.4 million from $49.7 million as contract manufacturing for the tanruprubart filings wound down, while G&A rose to $10.9 million from $7.3 million. The bigger news is financing: a strategic credit facility of up to $200 million with Oxford Finance, with $50 million drawn at closing and another $100 million available on vonaprument and tanruprubart milestones. Two binary readouts sit in the next two quarters — the tanruprubart BLA submission is expected in Q4 2026, and the ARCHER II Phase 3 Month 15 primary endpoint assessment is also expected in Q4 2026, with sub-study results in Q1 2027 if the DMC recommends the endpoint was met. The cash position plus the new facility removes near-term financing risk, but the stock still hinges on those two events.
At the time of this announcement, ANNX was trading at $4.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $801.9M. The 52-week trading range was $2.54 to $7.18. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.